Calcitonin gene-related peptide-targeted monoclonal antibodies (CGRP mAbs) are
increasingly being used as preventive treatments for migraine. Their effectiveness and …

Migraine is a leading cause of disability worldwide. A minority of individuals with migraine
develop resistant or refractory conditions characterised by≥ 8 monthly days of debilitating …

Background Erenumab has demonstrated effectiveness for prevention of migraine attacks,
but the treatment is costly, and a considerable proportion of patients do not respond to it. The …

Background Monoclonal antibodies (mAbs) targeting the Calcitonin Gene-Related Peptide
(CGRP) pathway are safe and effective treatments for migraine prevention. However, the …

Background Real-world data on the effectiveness of calcitonin gene-related peptide
monoclonal antibodies (CGRP mAbs) in migraine patients are needed. Methods We …

Abstract Purpose of Review Real-world data (RWD) has identified potential predictors of
response to anti-CGRP therapies in patients with chronic migraine (CM). This review aims to …

Background Although randomized controlled trials (RCTs) have shown that calcitonin gene-
related peptide (CGRP)-targeted monoclonal antibodies (CGRP mAbs) are an efficacious …

Background The complexity of clinical practice extends far beyond the controlled settings of
trials, and there is a need for real-world studies aimed at identifying which patients will …

Background Refractory migraine is a poorly described complication of migraine in which
migraine has chronified and become resistant to standard treatments. The true prevalence is …

Introduction Migraine pharmacological therapies targeting calcitonin gene-related peptide
(CGRP), including monoclonal antibodies and gepants, have shown clinical effect and …